Biohaven Pharmaceutical - BHVN Stock Forecast, Price & News

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Biohaven Pharmaceutical in the last twelve months. There are currently 5 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" BHVN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BHVN, but not buy additional shares or sell existing shares.
View BHVN analyst ratings or view top-rated stocks.

7 Wall Street research analysts have issued 1 year price targets for Biohaven Pharmaceutical's stock. Their BHVN share price forecasts range from $146.00 to $177.00. On average, they predict the company's share price to reach $157.17 in the next year. This suggests a possible upside of 6.2% from the stock's current price.
View analysts price targets for BHVN or view top-rated stocks among Wall Street analysts.

Biohaven Pharmaceutical's stock was trading at $137.81 at the start of the year. Since then, BHVN stock has increased by 7.4% and is now trading at $148.01.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 8th 2022.
View our BHVN earnings forecast.

Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN) posted its quarterly earnings results on Monday, November, 8th. The company reported ($2.63) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($2.40) by $0.23. The company had revenue of $135.74 million for the quarter, compared to the consensus estimate of $128.40 million. The company's revenue was up 668.5% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($3.27) EPS.

Based on aggregate information from My MarketBeat watchlists, some companies that other Biohaven Pharmaceutical investors own include AbbVie (ABBV), NVIDIA (NVDA), Micron Technology (MU), Advanced Micro Devices (AMD), Alibaba Group (BABA), ACADIA Pharmaceuticals (ACAD), QUALCOMM (QCOM), Pfizer (PFE), Sarepta Therapeutics (SRPT) and Abbott Laboratories (ABT).

(BHVN) raised $124 million in an initial public offering (IPO) on Thursday, May 4th 2017. The company issued 8,300,000 shares at $14.00-$16.00 per share. Morgan Stanley, Piper Jaffray and Barclays Capital acted as the underwriters for the IPO and William Blair and Needham & Company were co-managers.

Biohaven Pharmaceutical trades on the New York Stock Exchange (NYSE) under the ticker symbol "BHVN."

Biohaven Pharmaceutical's stock is owned by many different retail and institutional investors. Top institutional investors include State Street Corp (2.44%), Pentwater Capital Management LP (2.00%), Soros Fund Management LLC (1.76%), TIG Advisors LLC (1.44%), Allspring Global Investments Holdings LLC (1.29%) and JPMorgan Chase & Co. (1.23%). Insiders that own company stock include Declan Doogan, Elyse Stock, Eric Aguiar, George C Clark, Gregory Bailey, James Engelhart, John Tilton, John W Childs, Julia P Gregory, Kimberly Gentile, Robert Berman and William A Jones Jr.
View institutional ownership trends.

Shares of BHVN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of BHVN stock can currently be purchased for approximately $148.01.

Biohaven Pharmaceutical (NYSE:BHVN) has a market capitalization of $10.58 billion and generates $462.51 million in revenue each year. The company earns $-846,590,000.00 in net income (profit) each year or ($14.82) on an earnings per share basis.

The company employs 928 workers across the globe.

Biohaven Pharmaceutical's mailing address is 215 CHURCH STREET, NEW HAVEN CT, 06510. The official website for the company is www.biohavenpharma.com. The company can be reached via phone at (203) 404-0410 or via email at jennifer.porcelli@biohavenpharma.com.